Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ling Felce

MBiochem, DPhil

Postdoctoral Researcher

I completed my DPhil in Clinical Pharmacology from the Department of Oncology, University of Oxford, where the focus of my thesis was the production and testing of cancer vaccines based on different viral vectors. During the course of my research, I became interested in cancer immunology and the tumour microenvironment.

My first postdoctoral project was undertaken with Professor Alison Banham (NDCLS/RDM) where I investigated the targets of transcription factor FOXP1 in diffuse large B-cell lymphoma (DLBCL). In patients with DLBCL, FOXP1 can be used as a marker for poor prognosis, and may play a role in downregulating immune surveillance in tumours. I used CRISPR/Cas9  gene editing technology to knockout FOXP1 expression in a murine lymphoma cell line, and subsequently conducted tumour studies in vivo and carried out RNA-Seq to examine differential gene expression between parental and FOXP1-knockout cells.

In 2017 I joined Dr Gillian Farnie’s group at the Botnar Research Centre, where my research focus will be on the investigation of novel protein families, such as YEATS and Nudix in cancer. I aim to elucidate the functions and effects of these proteins on downstream pathways through CRISPR/Cas9 knockouts and next generation sequencing, thereby identifying new interaction partners and therapeutic targets. I will also be developing novel cellular assays in order to validate the cellular activity of chemical probes generated by groups in the Structural Genomics Consortium.